Latest News and Press Releases

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...

Glass Lewis Believes Velan’s “Fundamental Operational and Corporate Governance Case Fails to Bear Fruit” Glass Lewis Agrees the Current Settlement Offer is Fair and “Would Grant Velan Direct Board...

Comments on ISS Report Urges Shareholders to Vote “FOR” All of the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 28, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,...

Velan Rebuffed Very Reasonable Offer that Included a One Year Standstill, Designating Two New Independent Directors and an Incumbent Director Not Standing for Re-election in 2020 Despite Progenics’...

NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...

NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...

Board has Positioned Progenics to Maximize Value as a Result of Proactive and Deliberate Strategy Velan’s Baseless Criticisms about the Development of AZEDRA and 1095 Reveal a Fundamental Lack of...

NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...

Highlights Velan’s Faulty Assertions and Ongoing Efforts to Mislead Progenics Shareholders Urges Shareholders to Vote “For” All of Company’s Directors on the WHITE Proxy Card NEW YORK, June 19,...